Drug · CHEMBL1201576
RITUXIMAB
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. RITUXIMAB. Drugs and targets, record CHEMBL1201576. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1201576
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Blitzima, Mabthera, Mabthera rituxan, Ritemvia, Rituxan, Rituximab component of rituxan hycela, Rituzena (previously tuxella), Rixathon, Riximyo, Ruxience, Truxima
- ChEMBL
- Other names
ABP-798, ABP798, BI695500, Bi 695500, Bi-695500, Blitzima, CT-P10, GP-2013, Gp2013, HS-006, HS-006 (RITUXIMAB BIOSIMILAR), HS006, IDEC-102, IDEC-C 2B8, IDEC-C2B8, IDEC102, Mk-8808, Pf-05280586, R-105 IDEC-102, RG-105, RHCACD20MA, Riabni, Ritemvia, Rituximab (genetical recombination), Rituximab (rituxan), Rituximab abbs, Rituximab arrx, Rituximab biosimilar (amgen), Rituximab biosimilar (celltrion), Rituximab biosimilar (pfizer), Rituximab biosimilar - celltrion, Rituximab biosimilar -merck, Rituximab pvvr, Rituximab-abbs, Rituximab-arrx, Rituximab-boehringer ingelheim, Rituximab-ct-p10, Rituximab-pfizer, Rituximab-pvvr, Ruxience, SAIT-101, SAIT101, Truxima, Tuxella, Usp mab 001, monoclonal igg1, Zuberitamab
- ChEMBL
- Open Targets' highest stage
- Approval, for 9 of its 219 diseases, from ATC, ClinicalTrials.gov, DailyMed, EMA Human Drugs, PMDA and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| MS4A1 | B-lymphocyte antigen CD20 | B-lymphocyte antigen CD20 binding agent | BINDING AGENT | https://conductscience.org/library/genes/931 |
Source ChEMBL
Diseases219
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| diffuse large B-cell lymphoma | Preapproval | TTD | 448 | 446 | https://conductscience.org/library/drugs?q=MONDO_0018905 |
| non-Hodgkin lymphoma | Approval | DailyMed, EMA Human Drugs, PMDA and TTD | 307 | 289 | https://conductscience.org/library/drugs?q=MONDO_0018908 |
| B-cell chronic lymphocytic leukemia | Approval | ClinicalTrials.gov, DailyMed and EMA Human Drugs | 258 | 249 | https://conductscience.org/library/drugs?q=MONDO_0004948 |
| follicular lymphoma | Phase 3 | ClinicalTrials.gov and TTD | 248 | 242 | https://conductscience.org/library/drugs?q=MONDO_0018906 |
| mantle cell lymphoma | Phase 3 | ClinicalTrials.gov | 178 | 178 | https://conductscience.org/library/drugs?q=MONDO_0018876 |
| rheumatoid arthritis | Approval | DailyMed and EMA Human Drugs | 104 | 92 | https://conductscience.org/library/drugs?q=MONDO_0008383 |
| primary central nervous system lymphoma | Phase 3 | ClinicalTrials.gov | 71 | 71 | https://conductscience.org/library/drugs?q=MONDO_0002571 |
| lymphoma | Phase 3 | ClinicalTrials.gov and TTD | 67 | 66 | https://conductscience.org/library/drugs?q=MONDO_0005062 |
| marginal zone lymphoma | Phase 3 | ClinicalTrials.gov | 57 | 57 | https://conductscience.org/library/drugs?q=MONDO_0017604 |
| acute lymphoblastic leukemia | Approval | DailyMed | 53 | 52 | https://conductscience.org/library/drugs?q=MONDO_0004967 |
1 to 10 of 219Source Open Targets
See all 219 diseasesTrials2,250
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 4 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 10 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01476787 | Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma | Phase 3 | 1,030 | 2025-05-14 | rituximab | Its name | ClinicalTrials.gov |
| NCT00078949 | Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | Phase 3 | 849 | 2014-10-21 | rituximab | Its name | ClinicalTrials.gov |
| NCT01855750 | A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | Phase 3 | 838 | 2019-03-19 | rituximab | Its name | ClinicalTrials.gov |
| NCT00281918 | Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia | Phase 3 | 817 | 2011-03-29 | rituximab | Its name | ClinicalTrials.gov |
| NCT00486759 | A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma | Phase 3 | 787 | 2012-12-31 | rituximab | Its name | ClinicalTrials.gov |
| NCT01010061 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) | Phase 3 | 787 | 2014-04-01 | rituximab | Its name | ClinicalTrials.gov |
| NCT01998880 | CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) | Phase 3 | 787 | 2014-01-28 | rituximab | Its name | ClinicalTrials.gov |
| NCT02053610 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) | Phase 3 | 787 | 2014-10-10 | rituximab | Its name | ClinicalTrials.gov |
| NCT00307125 | Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies | Phase 2 | 757 | 2015-03-23 | rituximab | Its name | ClinicalTrials.gov |
| NCT00299104 | A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis | Phase 3 | 755 | 2011-08-10 | rituximab | Its name | ClinicalTrials.gov |
1 to 10 of 2,250
See all 2,250 trialsComparisons in its trials463
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Treatment Arm B: Ibrutinib+R-CHOP vs Treatment Arm A: Placebo+R-CHOP: deaths from any cause | 78 of 416 | 78 of 418 | 834 | NCT01855750 | Trial comparisons |
| Treatment Arm B: Ibrutinib+R-CHOP vs Treatment Arm A: Placebo+R-CHOP: serious adverse events | 221 of 416 | 143 of 418 | 834 | NCT01855750 | Trial comparisons |
| Fludarabine+Cyclophosphamide (FC) vs Fludarabine+Cyclophosphamide+Rituximab (FCR): serious adverse events | 164 of 398 | 186 of 402 | 800 | NCT00281918 | Trial comparisons |
| Bevacizumab + Rituximab + CHOP vs Placebo + Rituximab + CHOP: serious adverse events | 224 of 395 | 173 of 386 | 781 | NCT00486759 | Trial comparisons |
| Arm A vs Arm B: Number of Participants With Treatment Emergent Adverse Events (AEs) | 352 of 371 | 347 of 369 | 740 | NCT01724021 | Trial comparisons |
| Arm A vs Arm B: serious adverse events | 126 of 371 | 116 of 369 | 740 | NCT01724021 | Trial comparisons |
| Unselected Population (Participants With Any Comorbidity) vs Slow Go Subpopulation: serious adverse events | 85 of 485 | 44 of 196 | 681 | NCT01178086 | Trial comparisons |
| Rituximab + Chlorambucil (RClb) vs Obinutuzumab + Chlorambucil (GClb): serious adverse events | 124 of 321 | 150 of 336 | 657 | NCT02053610 | Trial comparisons |
| GP2013 vs Rituximab: To Evaluate the Overall Survival (OS) With up to 3 Years of Follow-up Post Randomization, as Assessed by the Number of Deaths | 29 of 312 | 31 of 315 | 627 | NCT01419665 | Trial comparisons |
| GP2013 vs Rituximab: To Evaluate the Progression Free Survival (PFS) With up to 3 Years of Follow-up Post Randomization | 97 of 312 | 78 of 315 | 627 | NCT01419665 | Trial comparisons |
1 to 10 of 463
See all 463 comparisons in its trialsPapers from its trials1,327
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials16
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Symbol Coding | 10 | 1 | ConductCognition |
| Verbal Learning | 6 | 1 | ConductCognition |
| Digit Span Test | 4 | 0 | ConductCognition |
| Paced Visual Serial Addition Test | 4 | 0 | ConductCognition |
| Trail Making Test A | 4 | 0 | ConductCognition |
| Trail Making Test B | 4 | 0 | ConductCognition |
| Verbal Fluency | 3 | 0 | ConductCognition |
| Complex Figure Copy and Recall | 2 | 0 | ConductCognition |
| Letter-Number Sequencing Task | 2 | 0 | ConductCognition |
| Block Copy Test | 1 | 0 | ConductCognition |
1 to 10 of 16
See all 16 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1201576
GET https://conductscience.org/api/drugs/v1/CHEMBL1201576/diseases?page=2